Nursing care
Terbutaline: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Terbutaline is a beta-2 agonist used off-label as a short-term tocolytic to suppress uterine contractions in preterm labour, and acutely for uterine hyperstimulation. It causes maternal tachycardia as an expected effect of beta stimulation, and that same tachycardia is the reason the drug is held or stopped if the heart rate climbs too far.
Why this drug and not another
Terbutaline relaxes uterine smooth muscle by stimulating beta-2 adrenergic receptors, making it useful for short-term suppression of contractions in preterm labour and for acute uterine hyperstimulation, including tachysystole caused by oxytocin.
It is not a first-line, long-term tocolytic. Its use is off-label and the FDA has warned against prolonged oral use or repeated injections beyond 48 to 72 hours because of cardiovascular risk to the mother. Other agents such as nifedipine or indomethacin are often preferred for sustained tocolysis.
Where terbutaline still has a clear role is speed: given subcutaneously, it acts quickly to relax the uterus in an acute hyperstimulation event, which is why it stays in the obstetric toolkit despite its narrow window of appropriate use.
Administration and timing
Terbutaline for tocolysis or hyperstimulation is typically given subcutaneously, not orally, in acute obstetric settings. Oral terbutaline for tocolysis is not recommended due to limited efficacy and the same cardiovascular concerns as injectable use.
Dosing is small-volume and short-course. It is not intended for maintenance therapy over days, and repeat dosing is limited and closely monitored against maternal heart rate and blood pressure between doses.
Confirm gestational age, fetal status, and the indication before administration. Tocolysis is meant to buy time, commonly for corticosteroid administration to accelerate fetal lung maturity or for transfer to a facility with a higher level of neonatal care, not to indefinitely delay delivery.
Monitoring parameters
Maternal heart rate and blood pressure are the core monitoring parameters, checked before and repeatedly after each dose. A rise in heart rate is an expected pharmacologic effect of beta-2 stimulation, not a surprise finding.
Continuous fetal heart rate monitoring is standard during administration, since fetal tachycardia can also occur from transplacental beta stimulation.
Monitor for signs of pulmonary oedema, particularly with prolonged or repeated dosing: dyspnoea, crackles, and falling oxygen saturation. Blood glucose should also be watched, since beta-2 agonists can cause hyperglycaria through glycogenolysis, and this matters more in mothers with diabetes.
Adverse effects to report
Expected effects include tremor, palpitations, mild tachycardia, and anxiety-like restlessness — these track with the drug's mechanism and don't automatically mean the dose should stop.
Report a maternal heart rate that climbs beyond the threshold set by the provider, usually around 120 beats per minute, or any chest pain, since these point toward the drug's most serious risk, cardiovascular compromise including arrhythmia and myocardial ischaemia.
Also report signs of pulmonary oedema, significant hypotension, or severe hyperglycaemia. These are the effects that turn an expected side effect profile into a reason to discontinue the drug rather than simply monitor through it.
Contraindications and cautions
Terbutaline is contraindicated in mothers with significant cardiac disease, uncontrolled hyperthyroidism, and poorly controlled diabetes, since beta-2 stimulation worsens all three.
Use it cautiously, or not at all, in women who are also receiving other agents that raise cardiovascular risk, and avoid combining it with other tocolytics that share cardiovascular side effects without close specialist oversight.
The FDA boxed warning specifically flags against use beyond 48 to 72 hours and against outpatient or home use with a terbutaline pump, due to reports of serious maternal cardiac events and death with prolonged exposure.
Teaching points the exam tests
Exam questions often centre on the idea that maternal tachycardia is expected with terbutaline, but that the drug is still held or discontinued when the heart rate rises past the set threshold — expected does not mean ignored.
Questions also test the purpose of tocolysis: it delays delivery briefly to allow corticosteroids to work or to enable transfer, not to stop labour indefinitely. Choosing an answer that treats terbutaline as a long-term solution is a common trap.
Expect questions distinguishing terbutaline's expected side effects, tremor, palpitations, mild tachycardia, from its danger signs, chest pain, marked tachycardia, or dyspnoea from pulmonary oedema. Knowing which column a symptom belongs in is usually the actual test.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our maternity and newborn practice questions are the closest set to what this page covers.
Common questions
Is maternal tachycardia with terbutaline a sign to stop the drug immediately?
Mild tachycardia is an expected effect of beta-2 stimulation and doesn't by itself mean stopping. The drug is held or discontinued when the heart rate exceeds the threshold set by the provider, commonly around 120 beats per minute, or if chest pain or other cardiac symptoms appear.
How long can terbutaline be used for tocolysis?
The FDA warns against use beyond 48 to 72 hours because of maternal cardiovascular risk with prolonged exposure. It is a short-term drug meant to buy time, not a maintenance tocolytic.
Why is terbutaline given subcutaneously rather than orally in obstetric emergencies?
Subcutaneous administration acts quickly, which matters for acute uterine hyperstimulation or rapid tocolysis. Oral terbutaline for tocolysis isn't recommended, since it has limited efficacy and carries the same cardiovascular concerns as injectable use without the speed advantage.
What should be monitored alongside heart rate when giving terbutaline?
Blood pressure, continuous fetal heart rate, signs of pulmonary oedema such as dyspnoea or crackles, and blood glucose, since beta-2 stimulation can cause hyperglycaemia. Fetal tachycardia can also occur from transplacental drug effect.
What is the actual goal of giving terbutaline in preterm labour?
To delay delivery briefly, usually to allow antenatal corticosteroids time to accelerate fetal lung maturity or to arrange transfer to a facility equipped for a preterm neonate. It is not intended to stop labour indefinitely.